Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 314

1.

Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.

Wang CY, Chao TT, Tai WT, Chang FY, Su WP, Chen YL, Chen PT, Weng CY, Yuan A, Shiau CW, Yu CJ, Chen KF.

J Thorac Oncol. 2014 Apr;9(4):488-96. doi: 10.1097/JTO.0000000000000107.

2.

Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells.

Liu CY, Tseng LM, Su JC, Chang KC, Chu PY, Tai WT, Shiau CW, Chen KF.

Breast Cancer Res. 2013;15(4):R63. Erratum in: Breast Cancer Res. 2017 Jan 11;19(1):5.

3.

Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.

Tai WT, Cheng AL, Shiau CW, Huang HP, Huang JW, Chen PJ, Chen KF.

J Hepatol. 2011 Nov;55(5):1041-8. doi: 10.1016/j.jhep.2011.01.047. Epub 2011 Feb 24.

PMID:
21354226
4.

A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.

Huang CY, Tai WT, Hsieh CY, Hsu WM, Lai YJ, Chen LJ, Shiau CW, Chen KF.

Cancer Lett. 2014 Jul 28;349(2):136-43. doi: 10.1016/j.canlet.2014.04.006. Epub 2014 Apr 13.

PMID:
24735751
5.

Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.

Tai WT, Shiau CW, Chen HL, Liu CY, Lin CS, Cheng AL, Chen PJ, Chen KF.

Cell Death Dis. 2013 Feb 7;4:e485. doi: 10.1038/cddis.2013.18.

6.

Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition.

Su TH, Shiau CW, Jao P, Liu CH, Liu CJ, Tai WT, Jeng YM, Yang HC, Tseng TC, Huang HP, Cheng HR, Chen PJ, Chen KF, Kao JH, Chen DS.

Proc Natl Acad Sci U S A. 2015 Jun 9;112(23):7243-8. doi: 10.1073/pnas.1507499112. Epub 2015 May 26.

7.

RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.

Su JC, Chiang HC, Tseng PH, Tai WT, Hsu CY, Li YS, Huang JW, Ko CH, Lin MW, Chu PY, Liu CY, Chen KF, Shiau CW.

Carcinogenesis. 2014 Dec;35(12):2807-14. doi: 10.1093/carcin/bgu210. Epub 2014 Oct 16.

PMID:
25322871
8.

Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.

Chen KF, Chen HL, Shiau CW, Liu CY, Chu PY, Tai WT, Ichikawa K, Chen PJ, Cheng AL.

Br J Pharmacol. 2013 Feb;168(3):658-72. doi: 10.1111/j.1476-5381.2012.02212.x.

9.

Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma.

Tai WT, Shiau CW, Chen PJ, Chu PY, Huang HP, Liu CY, Huang JW, Chen KF.

Hepatology. 2014 Jan;59(1):190-201. doi: 10.1002/hep.26640. Epub 2013 Dec 9. Erratum in: Hepatology. 2017 Jun;65(6):2135.

PMID:
23908138
10.

SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.

Su JC, Tseng PH, Wu SH, Hsu CY, Tai WT, Li YS, Chen IT, Liu CY, Chen KF, Shiau CW.

Neoplasia. 2014 Jul;16(7):595-605. doi: 10.1016/j.neo.2014.06.005. Epub 2014 Jul 18.

11.

SC-1, a sorafenib derivative, shows anti-tumor effects in osteogenic sarcoma cells.

Wang CT, Lin CS, Shiau CW, Chu PY, Hsiao CC, Chiang YL, Tai WT, Chen KF.

J Orthop Res. 2013 Feb;31(2):335-42. doi: 10.1002/jor.22218. Epub 2012 Aug 23.

12.

A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.

Chao TI, Tai WT, Hung MH, Tsai MH, Chen MH, Chang MJ, Shiau CW, Chen KF.

Cancer Lett. 2016 Feb 28;371(2):205-13. doi: 10.1016/j.canlet.2015.11.039. Epub 2015 Dec 8.

PMID:
26679051
13.

SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model.

Tai WT, Shiau CW, Li YS, Chen YL, Chu PY, Huang JW, Hsu CY, Hsu YC, Chen PJ, Chen KF.

Mol Cancer Ther. 2014 Jan;13(1):27-36. doi: 10.1158/1535-7163.MCT-13-0595. Epub 2013 Nov 25.

14.

Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells.

Liu CY, Su JC, Ni MH, Tseng LM, Chu PY, Wang DS, Tai WT, Kao YP, Hung MH, Shiau CW, Chen KF.

Breast Cancer Res Treat. 2014 Jul;146(1):71-84. doi: 10.1007/s10549-014-3000-0. Epub 2014 Jun 6.

PMID:
24903225
15.

A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation.

Chen KF, Su JC, Liu CY, Huang JW, Chen KC, Chen WL, Tai WT, Shiau CW.

Cancer Lett. 2012 Aug 1;321(1):27-35. doi: 10.1016/j.canlet.2012.03.023. Epub 2012 Mar 28.

PMID:
22465052
16.

CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.

Wang CY, Chao TT, Chang FY, Chen YL, Tsai YT, Lin HI, Huang YC, Shiau CW, Yu CJ, Chen KF.

Lung Cancer. 2014 Aug;85(2):152-60. doi: 10.1016/j.lungcan.2014.05.024. Epub 2014 Jun 5.

PMID:
24954871
17.

Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells.

Giovannetti E, Labots M, Dekker H, Galvani E, Lind JS, Sciarrillo R, Honeywell R, Smit EF, Verheul HM, Peters GJ.

Curr Pharm Des. 2013;19(5):927-39.

PMID:
22973961
18.

YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.

Kong J, Kong F, Gao J, Zhang Q, Dong S, Gu F, Ke S, Pan B, Shen Q, Sun H, Zheng L, Sun W.

Mol Cancer. 2014 Jan 13;13:7. doi: 10.1186/1476-4598-13-7.

19.

Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling.

Zhu F, Dai C, Fu Y, Loo JF, Xia D, Gao SP, Ma Z, Chen Z.

Oncotarget. 2016 Feb 23;7(8):9462-76. doi: 10.18632/oncotarget.7051.

20.

Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.

Tai WT, Cheng AL, Shiau CW, Liu CY, Ko CH, Lin MW, Chen PJ, Chen KF.

Mol Cancer Ther. 2012 Feb;11(2):452-63. doi: 10.1158/1535-7163.MCT-11-0412. Epub 2011 Dec 16.

Supplemental Content

Support Center